Table 4.
Gain in response rate vs gain in survival for anticancer drugs approved by FDA 2002-2012
Drug | Tumor type | Gain in response rate | p | Gain in OS, months | p |
---|---|---|---|---|---|
Oxaliplatin [156,171] |
Colorectal |
48% vs 32% |
0.006 |
5.6 |
<0.001 |
Pemetrexed [157] |
Mesothelioma |
41.3% vs 16.7% |
<0.0001 |
2.8 |
0.02 |
Bevacizumab [152] |
Colorectal |
44.8% vs 34.8% |
0.004 |
4.7 |
<0.0001 |
Gemcitabine [158] |
Breast |
41.4% vs 26.2% |
0.0002 |
2.8 |
0.0489 |
Erlotinib [37] |
Pancreas |
8.6% vs 8% |
NSa |
0.33 |
0.038 |
Docetaxel [159] |
Gastric |
37% vs 25% |
0.01 |
1.9 |
<0.001 |
Topotecan [160] |
Cervix |
27% vs 13% |
0.004 |
2.9 |
0.017 |
Bevacizumab [153] |
Colorectal |
22.7% vs 8.6% |
<0.0001 |
2.1 |
0.0011 |
Gemcitabine [161] |
Ovary |
42.7% vs 30.9% |
0.0016 |
0.7 |
0.83b |
Bevacizumab [151] |
NSCLC |
35% vs 15% |
<0.001 |
2 |
0.003 |
Docetaxel [162] |
Head and Neck |
68% vs 54% |
0.006 |
3.3 |
0.02 |
Lapatinib [163] |
Breast |
22% vs 14% |
0.09 |
NAc |
0.72 b |
Lapatinib [164] |
Breast |
23.7% vs 13.9% |
0.017 |
0.3 |
0.18 b |
Temsirolimus [165] |
Renal |
8.1% vs 4.8% |
NS |
1.1 |
0.70 b |
Ixabepilone [166,167] |
Breast |
35% vs 14% |
<0.0001 |
1.8 |
0.19 b |
Bevacizumab [154,155] |
Renal |
31% vs 13% |
0.0001 |
2.0 |
0.33 b |
Lapatinib [168] |
Breast (Her-2/neu +ve) |
28% vs 15% |
0.021 |
1.0 |
0.11 b |
Trastuzumab [169] |
Gastroesophageal |
47% vs 35% |
0.0017 |
2.7 |
0.0046 |
Cetuximab [170] | Head and neck | 36% vs 20% | <0.001 | 2.7 | 0.04 |
a. NS: not significant.
b. PFS differed significantly.
c. NA: not available.